Refine
Has Fulltext
- yes (8)
Is part of the Bibliography
- yes (8)
Document Type
- Journal article (7)
- Doctoral Thesis (1)
Language
- English (8)
Keywords
- Anaphylaxis (2)
- HIV (2)
- viral load (2)
- AIDS (1)
- CSF (1)
- Counterparty Risk (1)
- DAT (1)
- DNA replication (1)
- Double sensitization (1)
- Drug allergy (1)
- Drug reaction (1)
- Field sting (1)
- Financial Networks (1)
- Finanzielle Netzwerke (1)
- Finanzmathematik (1)
- HAND (1)
- HIV infections (1)
- Honey bee (1)
- Hymenoptera venom (1)
- Immunotherapy (1)
- Kapitalverflechtung (1)
- Mastocytosis (1)
- Non-steroidal anti-inflammatory drug (1)
- Numerical Asset Valuation (1)
- Pseudo-allergy (1)
- Relapse (1)
- Risikomanagement (1)
- Risk factor (1)
- Structrual Model (1)
- Systemic Risk (1)
- Systemisches Risiko (1)
- Treatment failure (1)
- Unternehmensbewertung (1)
- Vespula (1)
- antibiotic prophylaxis (1)
- blood (1)
- canal surgery (1)
- canaloplasty (1)
- cardiac surgery (1)
- cataract surgery (1)
- chlamydia (1)
- chlamydia infection (1)
- chlamydia trachomatis (1)
- circumferential viscodilation (1)
- dopamine (1)
- drug adherence (1)
- flexible microcatheter (1)
- glaucoma surgery (1)
- highly-active antiretroviral therapy (1)
- immune activation (1)
- macrophages (1)
- mitomycin C (1)
- months follow-up (1)
- nosocomial infection (1)
- open-angle glaucoma (1)
- phacocanaloplasty (1)
- phacotrabeculectomy (1)
- polymerase chain reaction (1)
- polymorphism (1)
- series (1)
- surgical outcomes (1)
- trabeculectomy (1)
- viral replication (1)
Institute
- Institut für Mathematik (7)
- Institut für Virologie und Immunbiologie (2)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (2)
- Augenklinik und Poliklinik (1)
- Institut für Informatik (1)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (1)
- Klinik und Poliklinik für Thorax-, Herz- u. Thorakale Gefäßchirurgie (1)
- Medizinische Klinik und Poliklinik II (1)
- Theodor-Boveri-Institut für Biowissenschaften (1)
Background
HIV-disease progression correlates with immune activation. Here we investigated whether corticosteroid treatment can attenuate HIV disease progression in antiretroviral-untreated patients.
Methods
Double-blind, placebo-controlled randomized clinical trial including 326 HIV-patients in a resource-limited setting in Tanzania (clinicaltrials.gov NCT01299948). Inclusion criteria were a CD4 count above 300 cells/μl, the absence of AIDS-defining symptoms and an ART-naïve therapy status. Study participants received 5 mg prednisolone per day or placebo for 2 years. Primary endpoint was time to progression to an AIDS-defining condition or to a CD4-count below 200 cells/μl.
Results
No significant change in progression towards the primary endpoint was observed in the intent-to-treat (ITT) analysis (19 cases with prednisolone versus 28 cases with placebo, p = 0.1407). In a per-protocol (PP)-analysis, 13 versus 24 study participants progressed to the primary study endpoint (p = 0.0741). Secondary endpoints: Prednisolone-treatment decreased immune activation (sCD14, suPAR, CD38/HLA-DR/CD8+) and increased CD4-counts (+77.42 ± 5.70 cells/μl compared to -37.42 ± 10.77 cells/μl under placebo, p < 0.0001). Treatment with prednisolone was associated with a 3.2-fold increase in HIV viral load (p < 0.0001). In a post-hoc analysis stratifying for sex, females treated with prednisolone progressed significantly slower to the primary study endpoint than females treated with placebo (ITT-analysis: 11 versus 21 cases, p = 0.0567; PP-analysis: 5 versus 18 cases, p = 0.0051): No changes in disease progression were observed in men.
Conclusions
This study could not detect any significant effects of prednisolone on disease progression in antiretroviral-untreated HIV infection within the intent-to-treat population. However, significant effects were observed on CD4 counts, immune activation and HIV viral load. This study contributes to a better understanding of the role of immune activation in the pathogenesis of HIV infection.